{"id":37018,"date":"2026-06-11T12:09:56","date_gmt":"2026-06-11T06:39:56","guid":{"rendered":"https:\/\/atsixty.com\/?p=37018"},"modified":"2026-06-11T12:10:28","modified_gmt":"2026-06-11T06:40:28","slug":"chronic-kidney-disease","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/","title":{"rendered":"Chronic Kidney Disease"},"content":{"rendered":"\n\n\n<meta charset=\"UTF-8\">\n<meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n<title>Morning Rounds \u00b7 Chronic Kidney Disease<\/title>\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&#038;family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,300&#038;display=swap\" rel=\"stylesheet\">\n<style>\n#nep02 *,#nep02 *::before,#nep02 *::after{box-sizing:border-box;margin:0;padding:0}\n#nep02{\n  --nep:#2A5470;\n  --nep-light:#3A7499;\n  --nep-pale:#EBF3F8;\n  --nep-dark:#1C3D52;\n  --correct:#2D6B47;--correct-bg:#EAF6EF;--correct-border:#3A9960;\n  --wrong:#B83232;--wrong-bg:#FDF0F0;--wrong-border:#E53935;\n  --ink:#1A2C38;--ink-mid:#3D5A6A;--ink-soft:#7A9BAD;\n  --line:#D8E6EE;--cream:#F4F8FB;--warm:#FAFCFE;\n  font-family:'Source Serif 4',Georgia,serif;\n  font-size:16px;color:var(--ink);background:var(--cream);\n  line-height:1.7;padding:0 0 64px;\n}\n#nep02 .mr-header{background:var(--nep);color:#F0F7FC;padding:34px 24px 28px;text-align:center}\n#nep02 .mr-eyebrow{font-size:0.68rem;letter-spacing:0.18em;text-transform:uppercase;font-weight:600;opacity:0.65;margin-bottom:10px}\n#nep02 .mr-title{font-family:'Playfair Display',serif;font-size:1.75rem;font-weight:700;line-height:1.2;margin-bottom:4px}\n#nep02 .mr-title em{font-style:italic;font-weight:400;opacity:0.88}\n#nep02 .mr-subtitle{font-size:0.82rem;opacity:0.7;margin-top:8px;font-style:italic}\n#nep02 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap}\n#nep02 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.73rem}\n#nep02 .mr-sentinel{height:1px}\n#nep02 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(26,44,56,0.08);padding:9px 16px;display:none}\n#nep02 .mr-progress.visible{display:block}\n#nep02 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#nep02 .mr-pips{display:flex;align-items:center;justify-content:center}\n#nep02 .mr-pip-wrap{display:flex;align-items:center}\n#nep02 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#nep02 .mr-pip-line.done{background:var(--nep)}\n#nep02 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0}\n#nep02 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#nep02 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#nep02 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#nep02 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--nep);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 6px rgba(26,44,56,0.05)}\n#nep02 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#nep02 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--nep);opacity:0.16;line-height:1;margin-top:-2px;flex-shrink:0}\n#nep02 .mr-meta{flex:1}\n#nep02 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--nep);opacity:0.75;margin-bottom:5px}\n#nep02 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#nep02 .mr-stem strong{font-weight:600}\n#nep02 .mr-stem em{font-style:italic}\n#nep02 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n#nep02 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#nep02 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent}\n#nep02 .mr-opt:hover{border-color:var(--nep);background:var(--nep-pale)}\n#nep02 .mr-opt.locked{cursor:default}\n#nep02 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#nep02 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#nep02 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#nep02 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#nep02 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#nep02 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#nep02 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#nep02 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s}\n#nep02 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#nep02 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#nep02 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#nep02 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#nep02 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n#nep02 .mr-exp{display:none;border-top:1px solid #c0dcea;background:linear-gradient(180deg,#e8f4f9 0%,#f2f9fc 100%);padding:13px 20px 15px}\n#nep02 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:#1e6080;margin-bottom:6px}\n#nep02 .mr-exp-text{font-size:0.86rem;color:#143a4e;line-height:1.68}\n#nep02 .mr-exp-text strong{font-weight:600}\n#nep02 .mr-exp-text em{font-style:italic}\n#nep02 .mr-img-wrap{margin-top:14px;background:var(--warm);border:1px solid var(--line);border-radius:8px;padding:14px;text-align:center}\n#nep02 .mr-img-wrap figcaption{font-size:0.73rem;color:var(--ink-soft);font-style:italic;margin-top:8px;line-height:1.4}\n#nep02 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#nep02 .mr-btn{background:var(--nep);color:#F0F7FC;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 8px rgba(42,84,112,0.28)}\n#nep02 .mr-btn:hover{background:var(--nep-dark)}\n#nep02 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--nep);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(26,44,56,0.08);overflow:hidden}\n#nep02 .mr-score-in{padding:28px 24px;text-align:center}\n#nep02 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600}\n#nep02 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--nep) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative}\n#nep02 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm)}\n#nep02 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#nep02 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--nep)}\n#nep02 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#nep02 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#nep02 .mr-score-net{font-size:0.9rem;color:var(--nep);font-weight:600;margin-bottom:4px}\n#nep02 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#nep02 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#nep02 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#nep02 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#nep02 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#nep02 .mr-band-s{background:var(--nep-pale);color:var(--nep)}\n#nep02 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--nep);color:var(--nep);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer}\n#nep02 .mr-retry:hover{background:var(--nep);color:#F0F7FC}\n@media(max-width:480px){#nep02 .mr-title{font-size:1.4rem}#nep02 .mr-num{font-size:1.7rem}#nep02 .mr-stem{font-size:0.9rem}#nep02 .mr-opt-text{font-size:0.86rem}}\n<\/style>\n\n<!-- CKD staging diagram for Q1 debrief -->\n<div id=\"nep02-img1\" style=\"display:none\">\n  <figure class=\"mr-img-wrap\">\n    <svg viewBox=\"0 0 560 195\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" style=\"width:100%;max-width:560px;display:block;margin:0 auto\">\n      <rect x=\"0\" y=\"0\" width=\"560\" height=\"195\" rx=\"8\" fill=\"#f0f6fa\"\/>\n      <text x=\"14\" y=\"18\" fill=\"#1A2C38\" font-size=\"9.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">CKD Staging \u2014 KDIGO 2012 (eGFR + Albuminuria)<\/text>\n      <!-- eGFR column header -->\n      <rect x=\"10\" y=\"22\" width=\"260\" height=\"20\" rx=\"3\" fill=\"#2A5470\"\/>\n      <text x=\"140\" y=\"35\" text-anchor=\"middle\" fill=\"#F0F7FC\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">eGFR-based Stage<\/text>\n      <!-- Albuminuria header -->\n      <rect x=\"278\" y=\"22\" width=\"272\" height=\"20\" rx=\"3\" fill=\"#1C3D52\"\/>\n      <text x=\"414\" y=\"35\" text-anchor=\"middle\" fill=\"#F0F7FC\" font-size=\"8.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Albuminuria Category (mg\/g or mg\/mmol)<\/text>\n\n      <!-- G1 -->\n      <rect x=\"10\" y=\"44\" width=\"260\" height=\"24\" rx=\"2\" fill=\"#d4e8f4\"\/>\n      <text x=\"18\" y=\"58\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">G1<\/text>\n      <text x=\"40\" y=\"58\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\">Normal \/ High<\/text>\n      <text x=\"200\" y=\"58\" text-anchor=\"middle\" fill=\"#2A5470\" font-size=\"8\" font-family=\"Georgia,serif\">eGFR &#x2265; 90<\/text>\n      <!-- G2 -->\n      <rect x=\"10\" y=\"70\" width=\"260\" height=\"24\" rx=\"2\" fill=\"#c4dff0\"\/>\n      <text x=\"18\" y=\"84\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">G2<\/text>\n      <text x=\"40\" y=\"84\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\">Mildly decreased<\/text>\n      <text x=\"200\" y=\"84\" text-anchor=\"middle\" fill=\"#2A5470\" font-size=\"8\" font-family=\"Georgia,serif\">60 \u2013 89<\/text>\n      <!-- G3a -->\n      <rect x=\"10\" y=\"96\" width=\"260\" height=\"24\" rx=\"2\" fill=\"#a8ceea\"\/>\n      <text x=\"18\" y=\"110\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">G3a<\/text>\n      <text x=\"40\" y=\"110\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\">Mildly\u2013moderately decreased<\/text>\n      <text x=\"200\" y=\"110\" text-anchor=\"middle\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\">45 \u2013 59<\/text>\n      <!-- G3b -->\n      <rect x=\"10\" y=\"122\" width=\"260\" height=\"24\" rx=\"2\" fill=\"#88bade\"\/>\n      <text x=\"18\" y=\"136\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">G3b<\/text>\n      <text x=\"40\" y=\"136\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\">Moderately\u2013severely decreased<\/text>\n      <text x=\"200\" y=\"136\" text-anchor=\"middle\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\">30 \u2013 44<\/text>\n      <!-- G4 -->\n      <rect x=\"10\" y=\"148\" width=\"260\" height=\"24\" rx=\"2\" fill=\"#5a9fc8\"\/>\n      <text x=\"18\" y=\"162\" fill=\"#fff\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">G4<\/text>\n      <text x=\"40\" y=\"162\" fill=\"#fff\" font-size=\"8\" font-family=\"Georgia,serif\">Severely decreased<\/text>\n      <text x=\"200\" y=\"162\" text-anchor=\"middle\" fill=\"#fff\" font-size=\"8\" font-family=\"Georgia,serif\">15 \u2013 29<\/text>\n      <!-- G5 -->\n      <rect x=\"10\" y=\"174\" width=\"260\" height=\"18\" rx=\"2\" fill=\"#2A5470\"\/>\n      <text x=\"18\" y=\"186\" fill=\"#F0F7FC\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">G5<\/text>\n      <text x=\"40\" y=\"186\" fill=\"#F0F7FC\" font-size=\"8\" font-family=\"Georgia,serif\">Kidney failure (ESRD)<\/text>\n      <text x=\"200\" y=\"186\" text-anchor=\"middle\" fill=\"#F0F7FC\" font-size=\"8\" font-family=\"Georgia,serif\">&lt; 15<\/text>\n\n      <!-- Albuminuria categories -->\n      <rect x=\"278\" y=\"44\" width=\"88\" height=\"50\" rx=\"2\" fill=\"#eaf6ef\"\/>\n      <text x=\"322\" y=\"60\" text-anchor=\"middle\" fill=\"#2D6B47\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">A1<\/text>\n      <text x=\"322\" y=\"73\" text-anchor=\"middle\" fill=\"#2D6B47\" font-size=\"7.5\" font-family=\"Georgia,serif\">Normal\u2013mildly<\/text>\n      <text x=\"322\" y=\"84\" text-anchor=\"middle\" fill=\"#2D6B47\" font-size=\"7.5\" font-family=\"Georgia,serif\">increased &lt;30<\/text>\n      <rect x=\"370\" y=\"44\" width=\"88\" height=\"50\" rx=\"2\" fill=\"#fff5e0\"\/>\n      <text x=\"414\" y=\"60\" text-anchor=\"middle\" fill=\"#7a5000\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">A2<\/text>\n      <text x=\"414\" y=\"73\" text-anchor=\"middle\" fill=\"#7a5000\" font-size=\"7.5\" font-family=\"Georgia,serif\">Moderately<\/text>\n      <text x=\"414\" y=\"84\" text-anchor=\"middle\" fill=\"#7a5000\" font-size=\"7.5\" font-family=\"Georgia,serif\">increased 30\u2013300<\/text>\n      <rect x=\"462\" y=\"44\" width=\"88\" height=\"50\" rx=\"2\" fill=\"#fdf0f0\"\/>\n      <text x=\"506\" y=\"60\" text-anchor=\"middle\" fill=\"#B83232\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">A3<\/text>\n      <text x=\"506\" y=\"73\" text-anchor=\"middle\" fill=\"#B83232\" font-size=\"7.5\" font-family=\"Georgia,serif\">Severely<\/text>\n      <text x=\"506\" y=\"84\" text-anchor=\"middle\" fill=\"#B83232\" font-size=\"7.5\" font-family=\"Georgia,serif\">increased &gt;300<\/text>\n      <!-- Note -->\n      <text x=\"322\" y=\"115\" text-anchor=\"middle\" fill=\"#3d5a6a\" font-size=\"7\" font-family=\"Georgia,serif\" font-style=\"italic\">A1 = low risk<\/text>\n      <text x=\"414\" y=\"115\" text-anchor=\"middle\" fill=\"#7a5000\" font-size=\"7\" font-family=\"Georgia,serif\" font-style=\"italic\">A2 = moderate risk<\/text>\n      <text x=\"506\" y=\"115\" text-anchor=\"middle\" fill=\"#B83232\" font-size=\"7\" font-family=\"Georgia,serif\" font-style=\"italic\">A3 = high \/ very high<\/text>\n      <text x=\"414\" y=\"145\" text-anchor=\"middle\" fill=\"#3d5a6a\" font-size=\"7.5\" font-family=\"Georgia,serif\">Risk = combined GFR + albuminuria category<\/text>\n      <text x=\"414\" y=\"158\" text-anchor=\"middle\" fill=\"#3d5a6a\" font-size=\"7\" font-family=\"Georgia,serif\" font-style=\"italic\">G1A1 or G2A1 = NOT CKD unless structural abnormality present<\/text>\n      <text x=\"414\" y=\"172\" text-anchor=\"middle\" fill=\"#2A5470\" font-size=\"7.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">CKD = abnormality persisting &gt; 3 months<\/text>\n    <\/svg>\n    <figcaption>\n      KDIGO 2012 CKD staging integrates eGFR (G1\u2013G5) with albuminuria category (A1\u2013A3). Risk of progression and cardiovascular events is determined by the combined cell in this heat-map grid. G1 or G2 with A1 does not constitute CKD unless structural kidney abnormality is present.\n    <\/figcaption>\n  <\/figure>\n<\/div>\n\n<!-- Anaemia of CKD pathway diagram for Q4 debrief -->\n<div id=\"nep02-img4\" style=\"display:none\">\n  <figure class=\"mr-img-wrap\">\n    <svg viewBox=\"0 0 520 148\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" style=\"width:100%;max-width:520px;display:block;margin:0 auto\">\n      <rect x=\"0\" y=\"0\" width=\"520\" height=\"148\" rx=\"8\" fill=\"#f0f6fa\"\/>\n      <text x=\"260\" y=\"16\" text-anchor=\"middle\" fill=\"#1A2C38\" font-size=\"9.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">Anaemia of CKD \u2014 Pathways &amp; Treatment Targets<\/text>\n      <!-- Box 1: Failing kidney -->\n      <rect x=\"10\" y=\"24\" width=\"115\" height=\"36\" rx=\"4\" fill=\"#d4e8f4\"\/>\n      <text x=\"67\" y=\"38\" text-anchor=\"middle\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">Failing kidney<\/text>\n      <text x=\"67\" y=\"51\" text-anchor=\"middle\" fill=\"#2A5470\" font-size=\"7.5\" font-family=\"Georgia,serif\">&#x2193; EPO production<\/text>\n      <!-- Arrow -->\n      <line x1=\"125\" y1=\"42\" x2=\"148\" y2=\"42\" stroke=\"#2A5470\" stroke-width=\"1.5\" marker-end=\"url(#arr)\"\/>\n      <defs><marker id=\"arr\" markerWidth=\"6\" markerHeight=\"6\" refX=\"3\" refY=\"3\" orient=\"auto\"><path d=\"M0,0 L6,3 L0,6 Z\" fill=\"#2A5470\"\/><\/marker><\/defs>\n      <!-- Box 2: Low EPO -->\n      <rect x=\"150\" y=\"24\" width=\"115\" height=\"36\" rx=\"4\" fill=\"#c4dff0\"\/>\n      <text x=\"207\" y=\"38\" text-anchor=\"middle\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">Low EPO<\/text>\n      <text x=\"207\" y=\"51\" text-anchor=\"middle\" fill=\"#2A5470\" font-size=\"7.5\" font-family=\"Georgia,serif\">&#x2193; RBC production<\/text>\n      <!-- Arrow -->\n      <line x1=\"265\" y1=\"42\" x2=\"288\" y2=\"42\" stroke=\"#2A5470\" stroke-width=\"1.5\" marker-end=\"url(#arr)\"\/>\n      <!-- Box 3: Normocytic anaemia -->\n      <rect x=\"290\" y=\"24\" width=\"130\" height=\"36\" rx=\"4\" fill=\"#a8ceea\"\/>\n      <text x=\"355\" y=\"38\" text-anchor=\"middle\" fill=\"#1C3D52\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">Normocytic anaemia<\/text>\n      <text x=\"355\" y=\"51\" text-anchor=\"middle\" fill=\"#1C3D52\" font-size=\"7.5\" font-family=\"Georgia,serif\">MCV normal; reticulocytes &#x2193;<\/text>\n      <!-- Box 4: Iron deficiency component -->\n      <rect x=\"430\" y=\"24\" width=\"82\" height=\"36\" rx=\"4\" fill=\"#fff5e0\"\/>\n      <text x=\"471\" y=\"36\" text-anchor=\"middle\" fill=\"#7a5000\" font-size=\"7.5\" font-family=\"Georgia,serif\" font-weight=\"bold\">+ Iron deficiency<\/text>\n      <text x=\"471\" y=\"48\" text-anchor=\"middle\" fill=\"#7a5000\" font-size=\"7\" font-family=\"Georgia,serif\">hepcidin blocks<\/text>\n      <text x=\"471\" y=\"58\" text-anchor=\"middle\" fill=\"#7a5000\" font-size=\"7\" font-family=\"Georgia,serif\">Fe absorption<\/text>\n      <!-- Treatment row -->\n      <rect x=\"10\" y=\"76\" width=\"155\" height=\"32\" rx=\"4\" fill=\"#eaf6ef\"\/>\n      <text x=\"87\" y=\"88\" text-anchor=\"middle\" fill=\"#2D6B47\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">ESA Therapy<\/text>\n      <text x=\"87\" y=\"100\" text-anchor=\"middle\" fill=\"#2D6B47\" font-size=\"7.5\" font-family=\"Georgia,serif\">Epoetin \/ Darbepoetin<\/text>\n      <rect x=\"175\" y=\"76\" width=\"155\" height=\"32\" rx=\"4\" fill=\"#eaf6ef\"\/>\n      <text x=\"252\" y=\"88\" text-anchor=\"middle\" fill=\"#2D6B47\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">Iron Supplementation<\/text>\n      <text x=\"252\" y=\"100\" text-anchor=\"middle\" fill=\"#2D6B47\" font-size=\"7.5\" font-family=\"Georgia,serif\">IV preferred in dialysis pts<\/text>\n      <rect x=\"340\" y=\"76\" width=\"170\" height=\"32\" rx=\"4\" fill=\"#fdf0f0\"\/>\n      <text x=\"425\" y=\"88\" text-anchor=\"middle\" fill=\"#B83232\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">Hb Target: 10\u201312 g\/dL<\/text>\n      <text x=\"425\" y=\"100\" text-anchor=\"middle\" fill=\"#B83232\" font-size=\"7.5\" font-family=\"Georgia,serif\">Avoid &gt;13 \u2014 thrombosis risk<\/text>\n      <!-- Footer note -->\n      <text x=\"260\" y=\"126\" text-anchor=\"middle\" fill=\"#3d5a6a\" font-size=\"7.5\" font-family=\"Georgia,serif\">Work up ESA hyporesponsiveness: iron deficiency, infection, aluminium toxicity, haemolysis, myeloma<\/text>\n      <text x=\"260\" y=\"140\" text-anchor=\"middle\" fill=\"#7A9BAD\" font-size=\"7\" font-family=\"Georgia,serif\" font-style=\"italic\">TSAT &gt;20% and ferritin &gt;100 ng\/mL (non-dialysis) or &gt;200 ng\/mL (dialysis) required before starting ESA<\/text>\n    <\/svg>\n    <figcaption>\n      Anaemia of CKD is primarily normocytic normochromic due to EPO deficiency. Hepcidin (elevated in CKD) blocks iron release from stores and intestinal absorption, adding a functional iron deficiency. ESA therapy targets Hb 10\u201312 g\/dL; exceeding 13 g\/dL increases stroke and thrombosis risk (CHOIR, CREATE trials).\n    <\/figcaption>\n  <\/figure>\n<\/div>\n\n<div id=\"nep02\">\n\n  <div class=\"mr-header\">\n    <div class=\"mr-eyebrow\">Morning Rounds \u00b7 Nephrology Series \u00b7 Round 02<\/div>\n    <div class=\"mr-title\">\n      Chronic Kidney Disease<br><em>Staging, Complications &amp; Progression<\/em>\n    <\/div>\n    <div class=\"mr-subtitle\">Five cases &middot; Read carefully &middot; Trust your instinct<\/div>\n    <div class=\"mr-chips\">\n      <span class=\"mr-chip\">5 Cases<\/span>\n      <span class=\"mr-chip\">+4 \/ &minus;1 scoring<\/span>\n      <span class=\"mr-chip\">Options reshuffled<\/span>\n    <\/div>\n  <\/div>\n\n  <div class=\"mr-sentinel\" id=\"nep02-sentinel\"><\/div>\n\n  <div class=\"mr-progress\" id=\"nep02-progress\">\n    <div class=\"mr-prog-inner\">\n      <div class=\"mr-pips\" id=\"nep02-pips\"><\/div>\n    <\/div>\n  <\/div>\n\n  <div class=\"mr-body\">\n    <div id=\"nep02-cases\"><\/div>\n    <div class=\"mr-submit-wrap\">\n      <button class=\"mr-btn\" id=\"nep02-submit\">Submit for Debrief<\/button>\n    <\/div>\n    <div class=\"mr-score\" id=\"nep02-score\">\n      <div class=\"mr-score-in\">\n        <div class=\"mr-score-ey\">Round Complete<\/div>\n        <div class=\"mr-ring\" id=\"nep02-ring\">\n          <div class=\"mr-ring-in\">\n            <span class=\"mr-ring-pct\" id=\"nep02-pct\">0%<\/span>\n            <span class=\"mr-ring-sub\">net<\/span>\n          <\/div>\n        <\/div>\n        <div class=\"mr-score-title\">Your Debrief<\/div>\n        <div class=\"mr-score-net\" id=\"nep02-net\"><\/div>\n        <div class=\"mr-verdict\" id=\"nep02-verdict\"><\/div>\n        <div class=\"mr-bands\">\n          <span class=\"mr-band mr-band-c\" id=\"nep02-ct-c\"><\/span>\n          <span class=\"mr-band mr-band-w\" id=\"nep02-ct-w\"><\/span>\n          <span class=\"mr-band mr-band-s\" id=\"nep02-ct-s\"><\/span>\n        <\/div>\n        <button class=\"mr-retry\" id=\"nep02-retry\">&#8635; New Round<\/button>\n      <\/div>\n    <\/div>\n  <\/div>\n\n<\/div><!-- end #nep02 -->\n\n<script>\n(function () {\n  'use strict';\n\n  var NS    = 'nep02';\n  var TOTAL = 5;\n  var MAX   = 20;\n  var LTRS  = ['A','B','C','D'];\n\n  var QS = [\n\n    {\n      id:      1,\n      tag:     'CKD &mdash; KDIGO Staging',\n      stem:    'A <strong>58-year-old man<\/strong> with type 2 diabetes has had two eGFR measurements of <strong>38 mL\/min\/1.73 m&sup2;<\/strong> taken <strong>4 months apart<\/strong>. His urine albumin-to-creatinine ratio (ACR) is <strong>220 mg\/g<\/strong> on two separate occasions. He has no haematuria or structural abnormality on ultrasound. What is his correct KDIGO CKD stage?',\n      correct: 'G3b A2',\n      opts: [\n        'G3b A2',\n        'G3a A3',\n        'G4 A2',\n        'G3b A1 \u2014 a single ACR value is insufficient to assign albuminuria category'\n      ],\n      exp:     'KDIGO 2012 stages CKD by <strong>eGFR (G1\u2013G5)<\/strong> and <strong>albuminuria (A1\u2013A3)<\/strong>, both confirmed on at least <strong>two occasions &ge;3 months apart<\/strong>. An eGFR of 38 falls in the <strong>G3b range (30\u201344)<\/strong>. An ACR of 220 mg\/g falls in <strong>A2 (moderately increased: 30\u2013300 mg\/g)<\/strong>. G3b A2 carries high risk of progression. A3 begins at &gt;300 mg\/g. G4 begins below 30 mL\/min. Both criteria being confirmed over 4 months satisfies the &gt;3-month duration requirement for CKD diagnosis. The commonest causes of CKD in India remain <strong>diabetic nephropathy and hypertensive nephropathy<\/strong>.',\n      imgId:   'nep02-img1'\n    },\n\n    {\n      id:      2,\n      tag:     'CKD &mdash; Metabolic Complications',\n      stem:    'A <strong>52-year-old woman<\/strong> with CKD G4 (eGFR 22) is reviewed in clinic. Her investigations show: serum calcium 7.8 mg\/dL, phosphate 5.8 mg\/dL, PTH 420 pg\/mL (normal 10\u201365), alkaline phosphatase elevated. She is not on dialysis. Which metabolic disorder best explains this constellation, and what is the first-line treatment?',\n      correct: 'Secondary hyperparathyroidism due to CKD-MBD; dietary phosphate restriction and phosphate binders',\n      opts: [\n        'Secondary hyperparathyroidism due to CKD-MBD; dietary phosphate restriction and phosphate binders',\n        'Primary hyperparathyroidism; surgical parathyroidectomy',\n        'Tertiary hyperparathyroidism; cinacalcet is contraindicated pre-dialysis',\n        'Vitamin D toxicity; stop all Vitamin D supplementation immediately'\n      ],\n      exp:     'This is classic <strong>CKD-Mineral Bone Disorder (CKD-MBD)<\/strong>. The sequence: failing kidneys cannot activate Vitamin D (1-alpha-hydroxylase deficiency) &#x2192; low 1,25-OH Vitamin D &#x2192; hypocalcaemia &#x2192; PTH rises (<strong>secondary hyperparathyroidism<\/strong>). Phosphate retention (GFR too low to excrete it) worsens the stimulus. First-line: <strong>dietary phosphate restriction<\/strong> + <strong>phosphate binders<\/strong> (calcium carbonate, sevelamer, or lanthanum carbonate). Active Vitamin D analogues (calcitriol, alfacalcidol) address the 1,25-OH D deficiency. <strong>Tertiary hyperparathyroidism<\/strong> refers to autonomous PTH secretion after prolonged secondary HPT \u2014 PTH remains elevated even after correction of calcium. Primary HPT causes <em>hypercalcaemia<\/em>, not hypocalcaemia.',\n      imgId:   null\n    },\n\n    {\n      id:      3,\n      tag:     'CKD &mdash; Slowing Progression',\n      stem:    'A <strong>45-year-old man<\/strong> with diabetic nephropathy (eGFR 55, ACR 380 mg\/g) is on metformin and a calcium channel blocker. His BP is 148\/92 mmHg. Which combination of interventions has the strongest evidence for slowing CKD progression in this patient?',\n      correct: 'ACE inhibitor or ARB + SGLT2 inhibitor; BP target &lt;130\/80 mmHg',\n      opts: [\n        'ACE inhibitor or ARB + SGLT2 inhibitor; BP target &lt;130\/80 mmHg',\n        'Beta-blocker + diuretic; strict glycaemic control with HbA1c &lt;6.0%',\n        'ARB + ACE inhibitor combined (dual blockade) for maximum antiproteinuric effect',\n        'Calcium channel blocker alone is preferred in diabetic nephropathy; RAS blockade risks hyperkalaemia'\n      ],\n      exp:     'Two interventions have robust evidence for slowing diabetic CKD progression beyond BP control alone. <strong>RAS blockade (ACEi or ARB)<\/strong> reduces intraglomerular pressure and proteinuria via efferent arteriolar dilation \u2014 it is the cornerstone agent for diabetic nephropathy with proteinuria. <strong>SGLT2 inhibitors<\/strong> (empagliflozin, dapagliflozin, canagliflozin) have demonstrated renal protection independent of glycaemic effect in multiple landmark trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY). The BP target in CKD with proteinuria is <strong>&lt;130\/80 mmHg<\/strong>. <strong>Dual RAS blockade (ACEi + ARB)<\/strong> was shown in the ONTARGET trial to increase AKI and hyperkalaemia risk without additional benefit \u2014 it is <em>contraindicated<\/em>. HbA1c target in CKD is individualised, typically 7\u20138%, not &lt;6% (hypoglycaemia risk).',\n      imgId:   null\n    },\n\n    {\n      id:      4,\n      tag:     'CKD &mdash; Anaemia Management',\n      stem:    'A <strong>60-year-old woman<\/strong> on haemodialysis three times weekly has Hb <strong>8.2 g\/dL<\/strong>, MCV 84 fL, serum ferritin <strong>85 ng\/mL<\/strong>, transferrin saturation (TSAT) <strong>16%<\/strong>. She is not on ESA therapy. What is the correct sequence of management?',\n      correct: 'Correct iron deficiency first with IV iron, then reassess before initiating ESA',\n      opts: [\n        'Correct iron deficiency first with IV iron, then reassess before initiating ESA',\n        'Start ESA immediately; iron stores are adequate since ferritin is within normal range',\n        'Oral iron supplementation is preferred in dialysis patients; IV iron risks anaphylaxis',\n        'Transfuse packed RBCs to Hb &gt;10 g\/dL; ESA is not indicated in dialysis patients'\n      ],\n      exp:     'Before starting ESA, <strong>iron stores must be adequate<\/strong>: KDIGO recommends <strong>TSAT &gt;20%<\/strong> and <strong>ferritin &gt;200 ng\/mL in dialysis patients<\/strong> (vs &gt;100 ng\/mL in non-dialysis CKD). This patient has TSAT 16% and ferritin 85 \u2014 both below target. Starting ESA with iron deficiency causes <strong>ESA hyporesponsiveness<\/strong> and wastes therapy. <strong>IV iron is preferred in dialysis patients<\/strong> because oral iron is poorly absorbed in the uremic gut and hepcidin (elevated in CKD\/inflammation) further blocks intestinal iron uptake. IV iron formulations (ferric carboxymaltose, iron sucrose) are safe when infused correctly. The Hb target on ESA is <strong>10\u201312 g\/dL<\/strong> \u2014 targeting &gt;13 g\/dL increased cardiovascular events in the CHOIR and CREATE trials. Blood transfusion is avoided where possible in dialysis patients awaiting transplantation (sensitisation risk).',\n      imgId:   'nep02-img4'\n    },\n\n    {\n      id:      5,\n      tag:     'CKD &mdash; Indications for RRT Initiation',\n      stem:    'A <strong>68-year-old man<\/strong> with CKD G5 (eGFR 9 mL\/min\/1.73 m&sup2;) is reviewed. He has mild nausea but no vomiting, no encephalopathy, no pericardial rub, serum potassium 5.2 mEq\/L, and bicarbonate 18 mEq\/L. He has been counselled about dialysis and prefers conservative management for now. Which statement best reflects current evidence on timing of dialysis initiation?',\n      correct: 'Dialysis should be initiated when uraemic symptoms, fluid overload, or metabolic complications develop \u2014 not based on eGFR alone',\n      opts: [\n        'Dialysis should be initiated when uraemic symptoms, fluid overload, or metabolic complications develop \u2014 not based on eGFR alone',\n        'Dialysis must be initiated at eGFR &lt;10 mL\/min regardless of symptoms to prevent sudden death',\n        'Early initiation at eGFR 10\u201314 improves survival compared to late initiation at eGFR &lt;7',\n        'Conservative management is appropriate only in patients over 75; this patient should start dialysis now'\n      ],\n      exp:     'The landmark <strong>IDEAL trial<\/strong> (Cooper et al., NEJM 2010) randomised patients to early (eGFR 10\u201314) vs late (eGFR 5\u20137) dialysis initiation and found <strong>no survival advantage<\/strong> to early start. Current KDIGO guidance recommends initiating RRT when patients develop <strong>uraemic symptoms<\/strong> (nausea, vomiting, encephalopathy, pericarditis, uraemic bleeding), <strong>refractory fluid overload<\/strong>, or <strong>metabolic complications unresponsive to medical therapy<\/strong> (refractory hyperkalaemia, acidosis), <strong>not<\/strong> at a fixed eGFR threshold. This patient has mild nausea only, stable electrolytes, and wishes to delay \u2014 <strong>watchful waiting with close monitoring is appropriate<\/strong>. Conservative (non-dialytic) kidney management is a valid pathway for all ages when consistent with patient goals, particularly in the elderly with multiple comorbidities.',\n      imgId:   null\n    }\n\n  ];\n\n  var answers  = {};\n  var answered = 0;\n  var shuffled = {};\n  var done     = false;\n\n  function byId(id) { return document.getElementById(id); }\n  function gid(suffix) { return byId(NS + '-' + suffix); }\n\n  function shuffleArr(arr) {\n    var a = arr.slice(), i, j, tmp;\n    for (i = a.length - 1; i > 0; i--) {\n      j = Math.floor(Math.random() * (i + 1));\n      tmp = a[i]; a[i] = a[j]; a[j] = tmp;\n    }\n    return a;\n  }\n\n  function countVal(val) {\n    var k, n = 0;\n    for (k in answers) {\n      if (answers.hasOwnProperty(k) && answers[k] === val) n++;\n    }\n    return n;\n  }\n\n  function buildPips() {\n    var cont = gid('pips'), i, q, wLine, wPip, line, pip;\n    cont.innerHTML = '';\n    for (i = 0; i < QS.length; i++) {\n      q = QS[i];\n      if (i > 0) {\n        wLine = document.createElement('div');\n        wLine.className = 'mr-pip-wrap';\n        line = document.createElement('div');\n        line.className = 'mr-pip-line';\n        line.id = NS + '-pl' + q.id;\n        wLine.appendChild(line);\n        cont.appendChild(wLine);\n      }\n      wPip = document.createElement('div');\n      wPip.className = 'mr-pip-wrap';\n      pip = document.createElement('div');\n      pip.className = 'mr-pip';\n      pip.id = NS + '-pip' + q.id;\n      pip.textContent = String(q.id);\n      wPip.appendChild(pip);\n      cont.appendChild(wPip);\n    }\n  }\n\n  function build() {\n    var cont, i, q, opts, card, top, numDiv, meta, tag, stem,\n        rule, optsDiv, expDiv, lbl, txt, imgDiv, imgSrc, j,\n        optEl, ltrSpan, txtSpan;\n\n    cont = gid('cases');\n    cont.innerHTML = '';\n    answers = {}; answered = 0; shuffled = {}; done = false;\n    gid('score').style.display = 'none';\n    buildPips();\n\n    for (i = 0; i < QS.length; i++) {\n      q = QS[i];\n      opts = shuffleArr(q.opts);\n      shuffled[q.id] = opts;\n\n      card = document.createElement('div');\n      card.className = 'mr-case';\n\n      top = document.createElement('div');\n      top.className = 'mr-case-top';\n\n      numDiv = document.createElement('div');\n      numDiv.className = 'mr-num';\n      numDiv.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n\n      meta = document.createElement('div');\n      meta.className = 'mr-meta';\n\n      tag = document.createElement('div');\n      tag.className = 'mr-tag';\n      tag.innerHTML = q.tag;\n\n      stem = document.createElement('div');\n      stem.className = 'mr-stem';\n      stem.innerHTML = q.stem;\n\n      meta.appendChild(tag);\n      meta.appendChild(stem);\n      top.appendChild(numDiv);\n      top.appendChild(meta);\n      card.appendChild(top);\n\n      rule = document.createElement('div');\n      rule.className = 'mr-rule';\n      card.appendChild(rule);\n\n      optsDiv = document.createElement('div');\n      optsDiv.className = 'mr-opts';\n\n      for (j = 0; j < opts.length; j++) {\n        optEl = document.createElement('div');\n        optEl.className = 'mr-opt';\n        optEl.id = NS + '-o' + q.id + '-' + j;\n        optEl.setAttribute('role', 'button');\n        optEl.setAttribute('tabindex', '0');\n\n        ltrSpan = document.createElement('span');\n        ltrSpan.className = 'mr-ltr';\n        ltrSpan.textContent = LTRS[j];\n\n        txtSpan = document.createElement('span');\n        txtSpan.className = 'mr-opt-text';\n        txtSpan.innerHTML = opts[j];\n\n        optEl.appendChild(ltrSpan);\n        optEl.appendChild(txtSpan);\n        optsDiv.appendChild(optEl);\n\n        (function (qid, oi) {\n          optEl.addEventListener('click', function () { pick(qid, oi); });\n        }(q.id, j));\n      }\n      card.appendChild(optsDiv);\n\n      expDiv = document.createElement('div');\n      expDiv.className = 'mr-exp';\n      expDiv.id = NS + '-exp' + q.id;\n\n      lbl = document.createElement('div');\n      lbl.className = 'mr-exp-lbl';\n      lbl.textContent = 'Debrief';\n\n      txt = document.createElement('div');\n      txt.className = 'mr-exp-text';\n      txt.innerHTML = q.exp;\n\n      expDiv.appendChild(lbl);\n      expDiv.appendChild(txt);\n\n      if (q.imgId) {\n        imgSrc = byId(q.imgId);\n        if (imgSrc) {\n          imgDiv = document.createElement('div');\n          imgDiv.innerHTML = imgSrc.innerHTML;\n          expDiv.appendChild(imgDiv);\n        }\n      }\n\n      card.appendChild(expDiv);\n      cont.appendChild(card);\n    }\n  }\n\n  function pick(qid, oi) {\n    var q, opts, i, el, correct;\n    if (answers[qid] !== undefined || done) return;\n\n    q = null;\n    for (i = 0; i < QS.length; i++) {\n      if (QS[i].id === qid) { q = QS[i]; break; }\n    }\n    if (!q) return;\n\n    opts = shuffled[qid];\n    correct = (opts[oi] === q.correct);\n    answers[qid] = correct ? 'c' : 'w';\n    answered++;\n\n    for (i = 0; i < opts.length; i++) {\n      el = byId(NS + '-o' + qid + '-' + i);\n      if (opts[i] === q.correct) {\n        el.className = 'mr-opt correct locked';\n      } else if (i === oi) {\n        el.className = 'mr-opt wrong locked';\n      } else {\n        el.className = 'mr-opt dimmed locked';\n      }\n    }\n\n    byId(NS + '-exp' + qid).style.display = 'block';\n    byId(NS + '-pip' + qid).className = 'mr-pip ' + (correct ? 'correct' : 'wrong');\n\n    if (qid > 1) {\n      var pl = gid('pl' + qid);\n      if (pl) pl.className = 'mr-pip-line done';\n    }\n  }\n\n  function showScore() {\n    var c, w, s, net, pct, disp, verdicts, vi, sc;\n    if (done) return;\n    done = true;\n\n    c = countVal('c');\n    w = countVal('w');\n    s = TOTAL - answered;\n    net  = (c * 4) - w;\n    pct  = Math.max(0, Math.round((net \/ MAX) * 100));\n    disp = Math.min(100, Math.max(0, pct));\n\n    gid('ring').style.background =\n      'conic-gradient(#2A5470 ' + disp + '%, #D8E6EE 0%)';\n\n    gid('pct').textContent = pct + '%';\n    gid('net').textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n\n    verdicts = [\n      [5, 'Perfect round. CKD mastered.'],\n      [4, 'Strong \\u2014 one nuance to revisit.'],\n      [3, 'Solid base \\u2014 consolidate the finer distinctions.'],\n      [2, 'Halfway there \\u2014 review the missed cases carefully.'],\n      [0, 'These cases repay close reading. Come back tomorrow.']\n    ];\n    gid('verdict').textContent = verdicts[4][1];\n    for (vi = 0; vi < verdicts.length; vi++) {\n      if (c >= verdicts[vi][0]) {\n        gid('verdict').textContent = verdicts[vi][1];\n        break;\n      }\n    }\n\n    gid('ct-c').textContent = '\\u2705 ' + c + ' Correct';\n    gid('ct-w').textContent = '\\u274C ' + w + ' Wrong';\n    gid('ct-s').textContent = '\\u23ED ' + s + ' Skipped';\n\n    sc = gid('score');\n    sc.style.display = 'block';\n    sc.scrollIntoView({ behavior: 'smooth', block: 'center' });\n  }\n\n  function tryInit() {\n    var sentinel = document.getElementById(NS + '-sentinel');\n    var submit   = document.getElementById(NS + '-submit');\n    var retry    = document.getElementById(NS + '-retry');\n    if (!sentinel || !submit || !retry) {\n      setTimeout(tryInit, 80);\n      return;\n    }\n    submit.addEventListener('click', showScore);\n    retry.addEventListener('click', function () {\n      build();\n      window.scrollTo(0, 0);\n    });\n    var bar = document.getElementById(NS + '-progress');\n    if (bar && window.IntersectionObserver) {\n      new IntersectionObserver(function (entries) {\n        bar.className = entries[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n      }, { threshold: 0 }).observe(sentinel);\n    }\n    build();\n  }\n\n  tryInit();\n\n}());\n<\/script>\n\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds \u00b7 Chronic Kidney Disease CKD Staging \u2014 KDIGO 2012 (eGFR + Albuminuria) eGFR-based Stage Albuminuria Category (mg\/g or mg\/mmol) G1 Normal \/ High eGFR &#x2265; 90 G2 Mildly decreased 60 \u2013 89 G3a Mildly\u2013moderately decreased 45 \u2013 59 G3b Moderately\u2013severely decreased 30 \u2013 44 G4 Severely decreased 15 \u2013 29 G5 Kidney failure&hellip;&nbsp;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[70,74,24,80],"tags":[],"class_list":["post-37018","post","type-post","status-publish","format-standard","hentry","category-clinical","category-morning-rounds","category-neet-pg","category-nephrology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chronic Kidney Disease - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chronic Kidney Disease - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds \u00b7 Chronic Kidney Disease CKD Staging \u2014 KDIGO 2012 (eGFR + Albuminuria) eGFR-based Stage Albuminuria Category (mg\/g or mg\/mmol) G1 Normal \/ High eGFR &#x2265; 90 G2 Mildly decreased 60 \u2013 89 G3a Mildly\u2013moderately decreased 45 \u2013 59 G3b Moderately\u2013severely decreased 30 \u2013 44 G4 Severely decreased 15 \u2013 29 G5 Kidney failure&hellip;&nbsp;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-11T06:39:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-11T06:40:28+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/chronic-kidney-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/chronic-kidney-disease\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Chronic Kidney Disease\",\"datePublished\":\"2026-06-11T06:39:56+00:00\",\"dateModified\":\"2026-06-11T06:40:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/chronic-kidney-disease\\\/\"},\"wordCount\":291,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"articleSection\":[\"Clinical\",\"Morning Rounds\",\"NEET PG\",\"Nephrology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/chronic-kidney-disease\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/chronic-kidney-disease\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/chronic-kidney-disease\\\/\",\"name\":\"Chronic Kidney Disease - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-06-11T06:39:56+00:00\",\"dateModified\":\"2026-06-11T06:40:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/chronic-kidney-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/chronic-kidney-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/chronic-kidney-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chronic Kidney Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chronic Kidney Disease - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/","og_locale":"en_US","og_type":"article","og_title":"Chronic Kidney Disease - atsixty","og_description":"Morning Rounds \u00b7 Chronic Kidney Disease CKD Staging \u2014 KDIGO 2012 (eGFR + Albuminuria) eGFR-based Stage Albuminuria Category (mg\/g or mg\/mmol) G1 Normal \/ High eGFR &#x2265; 90 G2 Mildly decreased 60 \u2013 89 G3a Mildly\u2013moderately decreased 45 \u2013 59 G3b Moderately\u2013severely decreased 30 \u2013 44 G4 Severely decreased 15 \u2013 29 G5 Kidney failure&hellip;&nbsp;","og_url":"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/","og_site_name":"atsixty","article_published_time":"2026-06-11T06:39:56+00:00","article_modified_time":"2026-06-11T06:40:28+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Chronic Kidney Disease","datePublished":"2026-06-11T06:39:56+00:00","dateModified":"2026-06-11T06:40:28+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/"},"wordCount":291,"commentCount":0,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"articleSection":["Clinical","Morning Rounds","NEET PG","Nephrology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/","url":"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/","name":"Chronic Kidney Disease - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-06-11T06:39:56+00:00","dateModified":"2026-06-11T06:40:28+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/chronic-kidney-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Chronic Kidney Disease"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=37018"}],"version-history":[{"count":1,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37018\/revisions"}],"predecessor-version":[{"id":37019,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37018\/revisions\/37019"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=37018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=37018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=37018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}